CME/CE Accreditation Information Return to Previous

A Collaborative Approach to IBD Management: Meaningful Engagement for Whole-Patient Care

Provided by Clinical Care Options, LLC in collaboration with RealCME


This CME program is supported by an educational grant from Takeda Pharmaceuticals USA, Inc.

Learning Objectives

Upon completion of this activity, learners should be able to:

  1. Identify the treatment options used for IBD
  2. Explore strategies for individualizing therapy in patients with IBD through collaborative care interactions to improve patient satisfaction and disease outcomes
  3. Identify strategies to increase empathy for patients as well as colleagues

Disclosure of Conflicts of Interest

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Bruce E. Sands MD, MS 
Dr. Burrill B. Crohn Professor of Medicine 
Chief of the Dr. Henry D. Janowitz 
Division of Gastroenterology 

Mount Sinai Hospital 
Chief, Division of Gastroenterology 
Mount Sinai Health System 
Director, Digestive Disease Institute 
Icahn School of Medicine at Mount Sinai 
New York, New York

Bruce E. Sands, MD, MS: researcher: Janssen, Theravance Biopharma R&D; consultant: Abivax, AbbVie, Alimentiv, Amgen, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calibr, Celltrion Healthcare, ClostraBio, Enthera, Evommune, Ferring, Galapagos, Gilead Sciences, GlaxoSmithKline, GossamerBio, Immunic, Index Pharmaceuticals, Innovation Pharmaceuticals, Ironwood Pharmaceuticals, Janssen, Kaleido, Kallyope, Lilly, MiroBio, MRM Health, Morphic Therapeutic, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Sun Pharma, Surrozen, Takeda, Target RWE, Teva Branded Pharmaceutical Products R&D, Thelium, Theravance Biopharma R&D, TLL Pharma, USWM Enterprises, Ventyx Biosciences, Viela Bio; ownership interest: Ventyx Biosciences.

Sunanda Kane, MD, MSPH
Professor of Medicine
Mayo Clinic
Department of Gastroenterology and Hepatology
Rochester, Minnesota

Sunanda Kane, MD, MSPH: consultant: Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, InveniAI, Kinetix, Predicta Med, Spherix Health, Seres Therapeutics, United Healthcare.


CCO staff and planners have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for HCPs who treat patients with IBD—gastroenterology HCPs, including advanced practice providers; and primary care HCPs, including advanced practice providers.


The goal of this CME/CE-certified curriculum is to establish impactful small-group interactions among community gastroenterologists, primary care providers, advanced practice providers, and other members of the healthcare team that will, through a variety of collaborative educational experiences, improve learners’ knowledge and competence in applying a collaborative approach to IBD management, thereby optimizing patient care and improving outcomes.

Accreditation Information

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Designation of Credit

Physician Continuing Medical Education

CCO designates this other activity, Gather-ed, for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.25 contact hours.

Physician Associate/Physician Assistant Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.25 AAPA Category 1 CME credits. Approval is valid until July 20, 2023. PAs should only claim commensurate with the extent of their participation.


Program Medium
This program has been made available online.

Instructions for Credit
Participation in this activity should be completed in approximately 3.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 21, 2022, through July 20, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity.
4. To claim the maximum amount of credit available, you must complete all of the following:

  • Completion of baseline assessment: 0.25 credit hours
  • Completion of three modules: 0.75 credit hour
  • Live Group Discussion 1: 0.5 credit hours
  • Live Group Discussion 2: 0.5 credit hours
  • Completion of group tasks: 1 credit hour
  • Completion of final assessment: 0.25 credit hours